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Kounis Syndrome (KS) is the contemporary occurrence of Acute Coronary Syndromes (ACS) with 
an allergic or hypersensitivity reaction. This syndrome has been reported in association with a 
variety of drugs, food, insect stings, environmental exposures and medical conditions. Cases of KS 
seem to be more often encountered in everyday clinical practice than anticipated. It is believed 
that the lack of awareness of this association may lead to underreporting. We report a case of 
KS secondary to diclofenac intake.
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Introduction
In 1991, Kounis and Zavras described the “syndrome of aller-
gic angina” and “allergic myocardial infarction”, currently 
known as Kounis syndrome (KS).1 KS is the concurrence of 
Acute Coronary Syndrome (ACS) with conditions associated 
with mast cell activation including allergic, hypersensitivi-
ty, anaphylactic and anaphylactoid reactions. The possible 
mechanism involves the release of inﬂ ammatory mediators 
through mast cell activation which induce coronary artery 
spasm and/or atheromatous plaque erosion or rupture.2 
KS has been increasingly reported in the literature and has 
been linked with several conditions, environmental exposures 
and a variety of drugs2,3, leading many experts to believe that 
KS is not rare, only “rarely diagnosed”.4
We report a case of KS secondary to Nonsteroidal Anti-
Inﬂ ammatory drug (NSAID) allergy.
Case report
A 62 year-old obese man with a history of bronchial asthma 
and hypertension was brought to our institute’s emergency 
room after syncope. Upon admission, he was confused, com-
plaining of precordial pain. He presented diaphoresis, with a 
cutaneous rash that affected his whole body, a pulse rate of 
100 bpm, SpO2 96% (FiO2 60%) and hypotension (78/34 mmHg). 
He had a prolonged expiratory time and diffuse wheezing at 
the base of both lungs. 
We recorded a 12-lead ECG, which showed ST segment 
elevation in the inferior leads. He was medicated with me-
toclopramide 10 mg intravenously (IV), morphine and aspirin 
500 mg IV. Because of refractory hypotension, we started 
dopamine infusion. Blood tests revealed elevated levels of 
Troponine I (0.8 ng.mL-1) and CKMB (7.7 ng.mL-1).
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He was submitted to cardiac catheterization, fai-
ling to show lesions on coronary vessels or contractility 
abnormalities. 
Due to his confusion upon admission, we could only 
take a detailed history one hour after the initial symptoms, 
revealing NSAID ingestion (75 mg of diclofenac) for shoul-
der pain ten minutes before the syncope accompanied by 
palmoplantar pruritus, vomiting, sweating, palpitations and 
chest pain. 
His family and past medical history revealed atopy, with 
frequent allergic conjunctivitis and rhinitis, food allergies 
(nut) and bronchial asthma. After the suspicion of an allergic 
event, he was medicated with hydrocortisone 200 mg and 
ranitidine 50 mg IV and was admitted in the Intensive Care 
Unit (ICU).
Within the ﬁ rst hours of admission, the patient became 
asymptomatic with normalization of ECG and improvement 
of laboratory ﬁ ndings (Troponine I - 0,05 ng.mL-1; CKMB - 1,2 
ng.mL-1). Echocardiography revealed no motility disorders 
of the heart wall muscle or other abnormalities. He was 
discharged of ICU 24 hours after admission. 
We obtained a tryptase (7,9 μg.L-1), immunoglobulin E 
(IgE) antibody level and complement proteins which were 
normal. We discussed intradermal provocative tests which 
were not performed for safety reasons.
Discussion
KS has two variants described.5 Type I variant includes 
patients with normal coronary arteries in whom the acu-
te allergic reaction induces coronary artery spasm. Type 
II variant deﬁ nes the patient with culprit but quiescent 
preexisting atheromatous disease in whom acute allergic 
reactions can induce plaque erosion or rupture to cause an 
acute myocardial infarction (MI). Our patient belongs in the 
KS type I variant.
The primary mechanism appears to be the presence of 
mast cells in heart tissue6,7 and subsequent degranulation in 
anaphylactic or anaphylactoid reaction setting with release 
of inﬂ ammatory mediators. This activation–degranulation can 
take place by several mechanisms, including via IgE, by his-
tamine-releasing factors from macrophages or T-lymphocytes 
or by anaphylatoxins from complement system activation.8-11 
The mediators released include tryptase, chymase, histami-
ne, platelet activating factor, cytokines and others, as well 
as prostaglandin and leukotriene synthesis.2 In many clinical 
and experimental studies, these mediators have been said 
to  induce coronary artery spasm and/or acute myocardial 
infarction.12,13
KS has been linked with several diseases (bronchial asth-
ma, urticaria, food allergy), environmental exposures (viper, 
wasp or bee venoms) and a variety of drugs used widely in 
daily clinical practice, such as antibiotics, analgesics, antine-
oplastics, contrast media, corticosteroids, intravenous anes-
thetics, nonsteroidal anti-inﬂ ammatory drugs and others.5 
There are recent reports of KS associated to rocuronium14 
and cisatracurium15 immediately following induction of ge-
neral anesthesia. Although cisatracurium is reportedly less 
allergenic than atracurium, it does not induce the release 
of histamine and has no clinically signiﬁ cant cardiovascular 
effects at doses eight times its ED95 (0.4 mg.kg-1), there are 
reports of severe anaphylactic reactions. The reported case 
by Ya-Ling Yang et al.15 not only conﬁ rms that cisatracurium 
can induce severe anaphylaxis, but also reveals that it can 
cause KS and highlights the possibility for cross-reaction 
between muscle relaxants.
It is difﬁ cult to identify the drugs that could result in 
anaphylactic reaction during anesthesia, since many drugs 
are administered in a relatively short time, especially during 
the induction phase. Skin tests may be useful in identifying 
the culprit agent.
In our case report, several factors support the diagnosis 
of KS, including a past medical history of atopy, bronchial 
asthma and food allergies, all known risk factors for ana-
phylactic reactions; short time interval between the ingestion 
of the drug (NSAIDs are a common cause of drug-induced 
anaphylaxis) and the development of signs and symptoms 
of anaphylaxis (involvement of the skin, gastrointestinal and 
respiratory system, reduced BP culminating in syncope)16 
with cardiac involvement. Although the patient complained 
of precordial pain, had ST elevation segments on ECG and 
elevation of troponines, the absence of lesions on coronary 
vessels or contractility abnormalities in cardiac catheteriza-
tion favors the hypothesis of coronary vasospasm. 
The NSAID intolerance is believed to be non-IgE me-
diated and occurs due to shunting of the arachidonic acid 
pathway by cyclooxigenase-1 inhibition with overproduction 
of cysteinyl leukotrienes and release of inﬂ ammatory me-
diators, including histamine and tryptase, from mast cells 
and eosinophils.17 Reactions appear to be medication spe-
ciﬁ c as there is no clinical cross reactivity with structurally 
unrelated NSAIDs.
The diagnosis of anaphylaxis is clinical, and the search 
for laboratory conﬁ rmation should not be allowed to delay 
the immediate management. Elevated serum histamine and 
tryptase levels strongly support the possibility of an ongoing 
allergic reaction, but they are impractical for routine use 
as they have very short half lives, remaining elevated for 10 
minutes maximum for histamine and 90 minutes for tryp-
tase.18 We found a normal tryptase level, but the clinical 
presentation did not allow us to take a detailed anamnesis 
upon admission and the sample was obtained several hours 
after the presentation. Nonetheless, a negative tryptase test 
does not exclude anaphylaxis.
Treatment may be challenging because it needs to con-
sider both cardiac and allergic symptoms simultaneously, 
and the drugs administered for these manifestations can 
aggravate an allergic reaction and heart function.
Cevik et al.19 have summarized recommendations con-
cerning the treatment of KS from available data, since most 
information about KS comes from case reports. The authors 
argue that: 
 
1) Aspirin has the potential risk of aggravating an ongoing 
anaphylactic reaction since it might shunt arachidonic 
acid into the leukotriene pathway with overproduction 
of leukotrienes. Therefore, the utility of aspirin in 
patients with KS is unknown.
2) Nitroglycerin causes hypotension and tachycar-
dia, which may further complicate anaphylactic 
reaction, but seems safe in KS if blood pressure is 
satisfactory. 
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3)  Beta-blockers may induce more vasospasm due to 
unopposed α-adrenergic effect and may offset some 
of the beneﬁ cial effects of epinephrine. 
4) Coronary spasm is very responsive to calcium channel 
blockers, so they may be considered the initial anti-
ischemic drug of choice in patients with KS. 
5) Morphine and meperidine should be used cautiously 
since these opiates can induce mast cell degranulation 
and aggravate the allergic reaction. Fentanyl and 
its derivatives show only a slight activation of mast 
cells and may be the drugs of choice when narcotic 
analgesia is necessary.  
6) Corticosteroids have a major role in the treatment 
of allergic reactions, and may prevent recurrent or 
protracted anaphylaxis. A meta-analysis of the studies 
of corticosteroid treatment in acute MI reported no 
harm and possible mortality beneﬁ t with these drugs 
in this setting. Therefore, their use is probably safe 
and appropriate. 
7) Epinephrine is the drug of choice in anaphylaxis, but 
in KS the risks may outweigh the beneﬁ ts. Epinephrine 
can aggravate the ischemia as well as induce coronary 
vasospasm and arrhythmias. The majority of epine-
phrine preparations contain sulﬁ te which itself may 
trigger anaphylaxis in sensitive individuals. It may also 
promote more vasospasm secondary to unopposed 
alpha-adrenergic effect in patients who have received 
beta-blocking agents. More case studies are needed 
to establish the appropriate use of epinephrine in 
patients with KS. 
8) Mast cell membrane stabilizers may be considered in 
KS.
Larger prospective studies are needed to establish deﬁ -
nitive treatment guidelines.
Involvement of the heart during an anaphylactic episode 
has been reported and an increasing number of cases in 
literature has been emerging. Although the exact patho-
physiologic mechanism remains unclear, KS should be born 
in mind when treating patients with no cardiovascular risk 
factors who experience ACS, especially when accompanied by 
symptoms resembling anaphylaxis and a testimony of recent 
allergen exposure. 
The management of these patients may be challenging 
and, unfortunately, guidelines have not been established 
yet.19
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